Transdermal Gasotransmitter Sensor (TAGS™)
TAGS is designed as a non-invasive point-of-care diagnostic technique for detection of endothelial dysfunction in the high risk diabetic population. It is based on a state-of-the-art sensing technique to detect the presence of and measure the concentration of biomarker of endothelial dysfunction, hydrogen sulfide [14]. Inspired by the office-based [17] system, the miniature home-based technology is currently under development at Exhalix.
TAGS wearable device the size of a men’s wrist watch, with all the built in electronics and features to provide real-time measurements of hydrogen sulfide diffusing through the skin. TAGS has been tested to detect hydrogen sulfide at less than 5-ppb, with a linear performance.
When attached to the skin, TAGS can discriminate the condition of high concentration (healthy microvascular blood perfusion, BOTTOM) from low concentration (abnormally low perfusion, TOP).